• Apogee Therapeutics CEO Michael Thomas Henderson sold 80,000 common shares on June 22, 2026 at a weighted average $132.54.
• Henderson held 1,015,987 shares following the sale.
• The transaction was made under a Rule 10b5-1 trading plan.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Apogee Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001104659-26-077426), on June 24, 2026, and is solely responsible for the information contained therein.